Drug Profile
OPC 33540
Latest Information Update: 26 Aug 2003
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical
- Class Anti-ischaemics; Antithrombotics; Organic chemicals; Quinolones
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemia; Thrombosis
Most Recent Events
- 26 Aug 2003 Discontinued - Preclinical for Ischaemia in Japan (unspecified route)
- 26 Aug 2003 Discontinued - Preclinical for Thrombosis in Japan (unspecified route)
- 11 May 1999 Preclinical development for Ischaemia in Japan (Unknown route)